Publication Date: 2021-04-15
ChAdOx1 nCOV-19 (Vaxzevria) is a vaccine against SARS-CoV-2 infection (COVID-19) developed by Oxford University and AstraZeneca that uses a replication-deficient chimpanzee adenoviral vector (ChAdOx1) containing the SARS-CoV-2 structural surface glycoprotein antigen (spike protein; nCoV-19) gene1.
Over the last few weeks, there have been several reports of thromboembolic events in subjects who had been administered Vaxzevria in the previous weeks. This led several European countries to decide to suspend its administration or, more recently, to limit it to subjects over 60 years of age. [ … ]
- Abstract viewed - 119 times
- PDF downloaded - 46 times